Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension

被引:7
作者
Satoh, T
Kimura, K
Okano, Y
Hirakata, M
Kawakami, Y
Kuwana, M
机构
[1] Keio Univ, Sch Med, Inst Adv Med Res, Shinjuku Ku, Tokyo 1608582, Japan
[2] Keio Univ, Sch Med, Dept Internal Med, Tokyo 1608582, Japan
[3] Kitasato Univ, Grad Sch Med Sci, Dept Lab Med, Sagamihara, Kanagawa 228, Japan
[4] Okano Clin, Abiko, Chiba, Japan
关键词
pulmonary arterial hypertension; autoantibody; mixed connective tissue disease; bone morphogenetic protein receptor-II; activin receptor-like kinase 1;
D O I
10.1093/rheumatology/keh449
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To examine whether autoantibodies against bone morphogenetic protein receptor-II (BMPR-II) or activin receptor-like kinase 1 (ALK-1) are associated with pulmonary arterial hypertension (PAH) in patients with mixed connective tissue disease (MCTD). Methods. We studied sera from 37 MCTD patients with or without PAH, six patients with idiopathic PAH, and 30 healthy controls. Circulating anti-BMPR-II and anti-ALK-1 antibodies were detected using immunoprecipitation of recombinant antigens generated by in vitro transcription/translation and indirect immunofluorescence of cultured cells that were induced to express these antigens by gene transfer. Anti-BMPR-II antibodies were further examined by immunoprecipitation and immunoblotting using a recombinant fragment of the extracellular domain of BMPR-II. Results. Serum anti-BMPR-II and anti-ALK-1 autoantibodies were not detected in MCTD patients irrespective of the presence or absence of PAH, or in patients with idiopathic PAH. Conclusions. Our finding does not support the hypothesis that autoantibody-mediated dysregulation of signals through BMPR-II or ALK-1 contributes to the development of PAH in patients with connective tissue diseases.
引用
收藏
页码:192 / 196
页数:5
相关论文
共 28 条
[1]   PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].
不详 .
ARTHRITIS AND RHEUMATISM, 1980, 23 (05) :581-590
[2]   Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor [J].
Atkinson, C ;
Stewart, S ;
Upton, PD ;
Machado, R ;
Thomson, JR ;
Trembath, RC ;
Morrell, NW .
CIRCULATION, 2002, 105 (14) :1672-1678
[3]   POLYMYOSITIS AND DERMATOMYOSITIS .2. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (08) :403-407
[4]  
Cines DB, 1998, BLOOD, V91, P3527
[5]   Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene [J].
Deng, ZM ;
Morse, JH ;
Slager, SL ;
Cuervo, N ;
Moore, KJ ;
Venetos, G ;
Kalachikov, S ;
Cayanis, E ;
Fischer, SG ;
Barst, RJ ;
Hodge, SE ;
Knowles, JA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (03) :737-744
[6]   Pulmonary hypertension in systemic sclerosis [J].
Denton, CP ;
Black, CM .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2003, 29 (02) :335-+
[7]  
Ebisawa T, 1999, J CELL SCI, V112, P3519
[8]   Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors [J].
Kawabata, M ;
Inoue, H ;
Hanyu, A ;
Imamura, T ;
Miyazono, K .
EMBO JOURNAL, 1998, 17 (14) :4056-4065
[9]   CLINICAL AND PROGNOSTIC ASSOCIATIONS BASED ON SERUM ANTINUCLEAR ANTIBODIES IN JAPANESE PATIENTS WITH SYSTEMIC-SCLEROSIS [J].
KUWANA, M ;
KABURAKI, J ;
OKANO, Y ;
TOJO, T ;
HOMMA, M .
ARTHRITIS AND RHEUMATISM, 1994, 37 (01) :75-83
[10]   Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases [J].
Kuwana, M ;
Kimura, K ;
Hirakata, M ;
Kawakami, Y ;
Ikeda, Y .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (09) :842-846